Vandortuzumab, a novel protein, shows a intriguing therapeutic compound targeting CD40, an key receptor involved in cellular reaction. The mechanism with action involves inhibiting CD40 signaling, potentially causing https://www.targetmol.com/compound/vandortuzumab